Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (RUBY-1)

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. ) Identifier:
First received: October 13, 2009
Last updated: September 29, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 28, 2015